(NASDAQ: COGT) Cogent Biosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.23%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.39%.
Cogent Biosciences's revenue in 2026 is $0.On average, 14 Wall Street analysts forecast COGT's revenue for 2026 to be $3,243,904,077, with the lowest COGT revenue forecast at $0, and the highest COGT revenue forecast at $7,142,561,933. On average, 13 Wall Street analysts forecast COGT's revenue for 2027 to be $59,479,690,177, with the lowest COGT revenue forecast at $18,610,329,301, and the highest COGT revenue forecast at $134,755,274,717.
In 2028, COGT is forecast to generate $123,958,492,010 in revenue, with the lowest revenue forecast at $40,083,786,187 and the highest revenue forecast at $168,638,863,980.